These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
616 related items for PubMed ID: 18937632
1. Systemic sclerosis: an update. Varga J. Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632 [Abstract] [Full Text] [Related]
2. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Földvari I, Furst DE, Müller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, EUSTAR Co-Authors. Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617 [Abstract] [Full Text] [Related]
3. Management of systemic sclerosis. Lim IG, Schrieber L. Isr Med Assoc J; 2002 Nov; 4(11 Suppl):953-7. PubMed ID: 12455189 [No Abstract] [Full Text] [Related]
4. Mechanisms and consequences of fibrosis in systemic sclerosis. Denton CP, Black CM, Abraham DJ. Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673 [Abstract] [Full Text] [Related]
5. New developments in the pathogenesis of systemic sclerosis. Sakkas LI. Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330 [Abstract] [Full Text] [Related]
6. [Systemic sclerosis]. Tamborrini G, Distler M, Distler O. Med Monatsschr Pharm; 2008 May; 31(5):162-70; quiz 171-2. PubMed ID: 18552072 [Abstract] [Full Text] [Related]
7. Molecular pathways as novel therapeutic targets in systemic sclerosis. Trojanowska M, Varga J. Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537 [Abstract] [Full Text] [Related]
8. Biomedical research. More than skin deep. Cahoon L. Science; 2008 Oct 31; 322(5902):667-9. PubMed ID: 18974325 [No Abstract] [Full Text] [Related]
9. [Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 2: treatment]. Zuber JP, Chizzolini C, Leimgruber A, Bart PA, Spertini F. Rev Med Suisse; 2006 Apr 19; 2(62):1058, 1060-6. PubMed ID: 16711151 [Abstract] [Full Text] [Related]
10. Animal models of scleroderma: lessons from transgenic and knockout mice. Derrett-Smith EC, Denton CP, Sonnylal S. Curr Opin Rheumatol; 2009 Nov 19; 21(6):630-5. PubMed ID: 19730378 [Abstract] [Full Text] [Related]
11. Systemic sclerosis/scleroderma: a treatable multisystem disease. Hinchcliff M, Varga J. Am Fam Physician; 2008 Oct 15; 78(8):961-8. PubMed ID: 18953973 [Abstract] [Full Text] [Related]
16. Future targets in the management of systemic sclerosis. Tyndall A, Matucci-Cerinic M, Müller-Ladner U. Rheumatology (Oxford); 2009 Jun 15; 48 Suppl 3():iii49-53. PubMed ID: 19487225 [Abstract] [Full Text] [Related]
17. [Management of patients with systemic sclerosis]. Wiesik-Szewczyk E, Olesińska M. Pol Merkur Lekarski; 2010 May 15; 28(167):421-3. PubMed ID: 20568411 [Abstract] [Full Text] [Related]